The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Nanotechnology for neurodegenerative disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Bondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175
Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.015 · Cited by 149 · cited 1×
“Also Canovi et al(13) synthesized NL decorated with an anti-Aβ monoclonal antibody, with high affinity for Aβ either in vitro or ex vivo on post-mortem AD brain samples; Mourtas et al(14) generated NL decorated with a curcumin derivative, binding Aβ with high affinity and inhibiting its aggregation in vitro.(15) A sim…”
Liu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148
Yang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135
Cited by
Nanoparticles for Brain Drug Delivery
Masserini, M. (2013) · ISRN Biochemistry · doi:10.1155/2013/238428 · Cited by 489
Self-citationIn vivo toxicity of cationic micelles and liposomes
Knudsen, K. B., Northeved, H., Kumar EK, P., Permin, A., Gjetting, T., Andresen, T. L., Larsen, S., Wegener, K. M., Lykkesfeldt, J., Jantzen, K., et al. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2014.08.004 · Cited by 356
Natural carbon-based quantum dots and their applications in drug delivery: A review
Nair, A., Haponiuk, J. T., Thomas, S., & Gopi, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110834 · Cited by 329
Addressing Dementia: The OECD Response
OECD (2015) · OECD Health Policy Studies · doi:10.1787/9789264231726-en · Cited by 327
Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324
Nano carriers for drug transport across the blood–brain barrier
Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., Cui, Y., Savina, I. N., Mikhalovska, L. I., Sandeman, S. R., et al. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1184272 · Cited by 282
Qi, Y., Guo, L., Jiang, Y., Shi, Y., Sui, H., & Zhao, L. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1762262 · Cited by 239
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability
Xiao, S., Zhou, D., Luan, P., Gu, B., Feng, L., Fan, S., Liao, W., Fang, W., Yang, L., Tao, E., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.021 · Cited by 169
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0284-14.2014 · Cited by 162
Self-citationTargeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Direct cellular delivery of human proteasomes to delay tau aggregation
Han, D. H., Na, H.-K., Choi, W. H., Lee, J. H., Kim, Y. K., Won, C., Lee, S.-H., Kim, K. P., Kuret, J., Min, D.-H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6633 · Cited by 88
Solid lipid nanoparticles loaded with lipoyl–memantine codrug: Preparation and characterization
Laserra, S., Basit, A., Sozio, P., Marinelli, L., Fornasari, E., Cacciatore, I., Ciulla, M., Türkez, H., Geyikoglu, F., & Di Stefano, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.001 · Cited by 72
“It has been reported that the benefit-risk balance deriving from the use of NPs for the treatment of CNS diseases should be carefully evaluated for each type of new engineered NP intended for brainspecific drug delivery (Re et al., 2012).”
BackgroundRhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
Al-azzawi, S., Masheta, D., Guildford, A. L., Phillips, G., & Santin, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103224 · Cited by 49
Mancini, S., Balducci, C., Micotti, E., Tolomeo, D., Forloni, G., Masserini, M., & Re, F. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.013 · Cited by 49
Self-citation
Metadata
- Authors
- Re, F., Gregori, M., & Masserini, M.
- Venue
- Maturitas
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 73
- Issue
- 1
- Pages
- 45-51
- ISSN
- 0378-5122 (ISSN-L)
- OpenAlex
- W2172396455
- Cited by
- 173
- References
- 5
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.